The now chronic nature of HIV has been a major advancement in AIDS care, but as with any chronic condition brings with it the recognition of other sequelae, including the HIV-associated neurocognitive disorder (HAND). In addition, as a natural consequence of the chronicity of infection and reduced new infection, the face of HIV infection is changing to an older population;soon over half of infected individuals will be 50 years of age or greater. As detailed in our Research Plan, we will now take the lessons others and we have learned about HIV and the brain and apply it to the changing epidemic - the graying of HIV, the nature of the effects on the brain of the chronic infection, means to treat HIV in the brain, and potential interaction with conditions linked to aging and other neurodegenerative disorders. We will set about this through the Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center as described in this proposal. We will accomplish four Action Items novel Biomarkers, the Role of Macrophages CNS Penetrating Antiviral Therapeutics, and the Effects on Chronic CNS Infection on Neurons, and support our investigators'research efforts through our Cores (Administrative, Biophysical Assessment Cells/Tissues/Animals, Developmental, International, Phenomics, Systems Biology, and Therapeutics). Our goals driven by our framework: researching of the chronicity of HIV infection in the CNS with a systems biology approach.
While HIV infected individuals are living longer, damaging effects of HIV persists on the brain, and as infected individuals age, may interact with other neurodegenerative disorders. Here we will investigate this change in the epidemic, and research new ways to diagnose, predict, treat, and prevent brain damage induced by HIV.
|Villeneuve, Lance M; Purnell, Phillip R; Stauch, Kelly L et al. (2016) HIV-1 transgenic rats display mitochondrial abnormalities consistent with abnormal energy generation and distribution. J Neurovirol :|
|Li, Weizhe; Tong, Hsin-I; Gorantla, Santhi et al. (2016) Neuropharmacologic Approaches to Restore the Brain's Microenvironment. J Neuroimmune Pharmacol 11:484-94|
|Singh, Dhirender; McMillan, JoEllyn; Hilaire, James et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) 11:1913-27|
|Sajja, Balasrinivasa R; Bade, Aditya N; Zhou, Biyun et al. (2016) Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2RÎ³c(null) Mouse Brain Atlas. J Neuroimmune Pharmacol 11:133-41|
|Jaeger, Philipp A; Lucin, Kurt M; Britschgi, Markus et al. (2016) Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener 11:31|
|Bade, Aditya N; Gorantla, Santhi; Dash, Prasanta K et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Mol Neurobiol 53:3286-97|
|Zhang, Gang; Guo, Dongwei; Dash, Prasanta K et al. (2016) The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12:109-22|
|Burns, Ariel; Ciborowski, Pawel (2016) Acute exposure to methamphetamine alters TLR9-mediated cytokine expression in human macrophage. Immunobiology 221:199-207|
|Yang, Lu; Yao, Honghong; Chen, Xufeng et al. (2016) Role of Sigma Receptor in Cocaine-Mediated Induction of Glial Fibrillary Acidic Protein: Implications for HAND. Mol Neurobiol 53:1329-42|
|Dong, Weiguo; Embury, Christine M; Lu, Yaman et al. (2016) The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-Î² degradation. J Neuroinflammation 13:184|
Showing the most recent 10 out of 337 publications